Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 64 entries
View as:

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT01201902 Org: User:
Start: 10/31/09 End: 07/31/10 Due: 07/31/11

Study of Idursulfase-beta (GC1111) in Hunter Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT02663024 Org: User:
Start: 12/31/16 End: 06/30/20 Due: 06/30/21

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT02063789 Org: User:
Start: 06/30/14 End: 04/30/16 Due: 04/30/17

A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children

Phase: N/A Priority: Normal
NCT ID: NCT02541253 Org: User:
Start: 09/30/15 End: 06/30/16 Due: 06/30/17

Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy

Phase: N/A Priority: Normal
NCT ID: NCT01696305 Org: User:
Start: 12/31/12 End: 02/28/14 Due: 02/28/15

Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.

Phase: N/A Priority: Normal
NCT ID: NCT02067117 Org: User:
Start: 10/31/10 End: 11/30/10 Due: 11/30/11

HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102

Phase: N/A Priority: Normal
NCT ID: NCT03519113 Org: User:
Start: 03/29/18 End: 09/30/22 Due: 09/30/23

GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock

Phase: N/A Priority: Normal
NCT ID: NCT01315496 Org: User:
Start: 10/31/09 End: 12/31/13 Due: 12/31/14

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Phase: N/A Priority: Normal
NCT ID: NCT01619046 Org: User:
Start: 03/31/13 End: 09/30/15 Due: 09/30/16

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02367638 Org: User:
Start: 03/31/15 End: - Due: -

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

Phase: N/A Priority: Normal
NCT ID: NCT02783482 Org: User:
Start: 10/31/16 End: 07/31/19 Due: 07/31/20

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT02915809 Org: User:
Start: 10/31/16 End: 05/31/17 Due: 05/31/18

Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection

Phase: N/A Priority: Normal
NCT ID: NCT01606163 Org: User:
Start: 08/31/12 End: 12/31/13 Due: 12/31/14

A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03454620 Org: User:
Start: 04/02/18 End: 01/10/22 Due: 01/10/23

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

Phase: N/A Priority: Normal
NCT ID: NCT02813486 Org: User:
Start: 06/30/16 End: 11/30/16 Due: 11/30/17

COVIDIG (COVID-19 Hyper-ImmunoGlobulin)

Phase: N/A Priority: Normal
NCT ID: NCT04555148 Org: User:
Start: 09/19/20 End: 04/23/21 Due: 04/23/22

Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01987011 Org: User:
Start: 08/31/13 End: 03/31/14 Due: 03/31/15

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Phase: N/A Priority: Normal
NCT ID: NCT05422508 Org: User:
Start: 07/05/22 End: 06/30/27 Due: 06/30/28

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01954238 Org: User:
Start: 08/31/13 End: 05/31/14 Due: 05/31/15

Evaluate the Safety and Exploratory Efficacy of GC1119

Phase: N/A Priority: Normal
NCT ID: NCT01653444 Org: User:
Start: 11/30/12 End: 10/31/15 Due: 10/31/16

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04238975 Org: User:
Start: 10/14/19 End: 05/31/21 Due: 05/31/22

Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT03363178 Org: User:
Start: 12/14/17 End: 03/31/18 Due: 03/31/19

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Phase: N/A Priority: Normal
NCT ID: NCT01301898 Org: User:
Start: 05/31/10 End: 03/31/11 Due: 03/31/12

A Study of GC1111 in Hunter Syndrom Patients

Phase: N/A Priority: Normal
NCT ID: NCT03920540 Org: User:
Start: 03/09/17 End: 02/15/22 Due: 02/15/23

Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)

Phase: N/A Priority: Normal
NCT ID: NCT02249221 Org: User:
Start: 10/31/14 End: 11/30/14 Due: 11/30/15